Divi's Laboratories · NSE: DIVISLAB · BSE: 532488
Q2 FY22 results · Jul–Sep 2021
Divi's Laboratories reported revenue from operations of ₹1,987.51 crore (up 13.6% from Q2 FY21) and net profit of ₹606.46 crore (up 16.7% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,987.51 | 1,749.30 | +13.6% | 1,960.64 | +1.4% |
| Other income | 19.11 | 13.64 | +40.1% | 35.97 | −46.9% |
| Total income | 2,006.62 | 1,762.94 | +13.8% | 1,996.61 | +0.5% |
| Profit before tax | 759.62 | 693.49 | +9.5% | 814.48 | −6.7% |
| Net profit for the period | 606.46 | 519.59 | +16.7% | 557.11 | +8.9% |
| Attributable to shareholders of the company | 606.64 | 519.59 | +16.8% | 558.88 | +8.5% |
| EPS, basic (₹) | 22.84 | 19.57 | +16.7% | 20.99 | +8.8% |
| Net margin (%) | 30.5 | 29.7 | 28.4 |
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,967.86 | 1,713.78 | +14.8% | 1,950.16 | +0.9% |
| Other income | 19.11 | 13.64 | +40.1% | 35.55 | −46.2% |
| Total income | 1,986.97 | 1,727.42 | +15.0% | 1,985.71 | +0.1% |
| Profit before tax | 760.44 | 685.03 | +11.0% | 813.77 | −6.6% |
| Net profit for the period | 606.39 | 513.30 | +18.1% | 551.97 | +9.9% |
| EPS, basic (₹) | 22.84 | 19.34 | +18.1% | 20.79 | +9.9% |
| Net margin (%) | 30.8 | 30.0 | 28.3 |
Consolidated
- Filed with BSE
- 06 Nov 2021, 15:30 IST
- Board meeting
- 06 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Nov 2021, 15:30 IST
- Board meeting
- 06 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE